Bicara Therapeutics Inc. ... (BCAX)
NASDAQ: BCAX
· Real-Time Price · USD
11.54
0.07 (0.61%)
At close: Aug 19, 2025, 3:59 PM
11.51
-0.22%
After-hours: Aug 19, 2025, 04:25 PM EDT
0.61% (1D)
| Bid | 9.57 |
| Market Cap | 629.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -90.06M |
| EPS (ttm) | -4.66 |
| PE Ratio (ttm) | -2.48 |
| Forward PE | -3.76 |
| Analyst | Buy |
| Ask | 12.5 |
| Volume | 186,698 |
| Avg. Volume (20D) | 770,130 |
| Open | 11.85 |
| Previous Close | 11.47 |
| Day's Range | 11.37 - 11.85 |
| 52-Week Range | 7.80 - 28.09 |
| Beta | -1.49 |
About BCAX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCAX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-40.8%
Bicara Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
2 months ago
+7.33%
Bicara Therapeutics shares are trading lower after the company announced a publication of phase 1/1b trial data for ficerafusp alfa showing mixed results, with median survival still unreached and limited clarity on long-term efficacy.
2 months ago · seekingalpha.com
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From MerusMRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative...
2 months ago · seekingalpha.com
Bicara: Stock Decline On FICERA Abstract Release Creates Buying OpportunityThe recent stock drop in Bicara Therapeutics Inc. is an overreaction, as the full phase 1/1b data—including key OS results—has yet to be released. BCAX interim data for FICERA plus KEYTRUDA in HPV-neg...